Search results for "thrombolytic therapy"

showing 10 items of 61 documents

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ER…

2020

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

ORAL ANTICOAGULANT-THERAPYdiagnosis[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematologyEmbolectomyGuidelineRECURRENT VENOUS THROMBOEMBOLISM0302 clinical medicinePregnancyDaily practiceDiagnosisPulmonary medicineVenous thrombosisPulmonary MedicineThrombolytic TherapyDEEP-VEIN THROMBOSISDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUShealth care economics and organizationsRisk assessmentddc:616RIGHT-VENTRICULAR DYSFUNCTIONDisease ManagementShockMOLECULAR-WEIGHT HEPARINThrombolysishumanities3. Good healthPulmonary embolismEuropeAnticoagulation; Biomarkers; Diagnosis; Dyspnoea; Echocardiography; Embolectomy; Guidelines; Heart failure; Pregnancy; Pulmonary embolism; Right ventricle; Risk assessment; Shock; Thrombolysis; Treatment; Venous thromboembolism; Venous thrombosismedicine.veinEchocardiographyAcute DiseaseRight ventricleMedical emergencyCardiology and Cardiovascular MedicineRisk assessmentguidelines; pulmonary embolism; venous thrombosis; shock dyspnoea; heart failure: right ventricle: diagnosis; risk assessment: echocardiography; biomarkers; treatment; anticoagulation; thrombolysis; pregnancy; venous thromboembolism; embolectomyDiagnosiVenous thromboembolismthrombolysiseducationCardiologyMEDLINEThrombolysiHeart failure610 Medicine & healthGuidelinesInferior vena cava2705 Cardiology and Cardiovascular MedicineEXTRACORPOREAL MEMBRANE-OXYGENATION03 medical and health sciencesAnticoagulationMedicalDyspnoeamedicineHumansRIGHT HEART THROMBIVENTILATION-PERFUSION SCINTIGRAPHYshock dyspnoeaHealth professionalsbusiness.industryINFERIOR VENA-CAVA10031 Clinic for Angiologyheart failure: right ventricle: diagnosisPulmonary embolismAnticoagulantsbiomarkersrisk assessment: echocardiography030229 sport sciencesBiomarkermedicine.diseaseTreatmentINHALED NITRIC-OXIDESocietiesbusinessBiomarkers
researchProduct

Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials.

2017

Defining a “higher-risk” population among intermediate-risk patients with pulmonary embolism included in PEITHO http://ow.ly/JM7u30hcSgN

Pulmonary and Respiratory MedicineResearch designAdultRiskmedicine.medical_specialtymedicine.medical_treatmentPopulationMEDLINEHemorrhageComorbidity030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineText miningFibrinolytic AgentsmedicineHumansThrombolytic Therapy030212 general & internal medicineProspective StudiesIntensive care medicineeducationProspective cohort studyeducation.field_of_studybusiness.industryPatient SelectionAnticoagulantsThrombolysismedicine.diseasePrognosisComorbidityPulmonary embolismTreatment OutcomeEchocardiographyResearch DesignTenecteplasebusinessPulmonary EmbolismThe European respiratory journal
researchProduct

Progress in the management of acute pulmonary embolism.

2015

Purpose of review Pulmonary embolism is a major contributor to global disease burden worldwide. The 2014 guidelines of the European Society of Cardiology, endorsed by the European Respiratory Society, emphasize the need for initial and advanced risk stratification as well as risk-adapted treatment to ensure the highest quality of care. This review summarizes the progress in pulmonary embolism diagnosis, risk assessment, and treatment. Recent findings Major advances of the past 12 months include age-related biomarker cutoff levels for optimising pulmonary embolism diagnosis and risk stratification; detection of (isolated) subsegmental pulmonary embolism by computed tomographic pulmonary angi…

Pulmonary and Respiratory MedicineVena cava filtersmedicine.medical_specialtybusiness.industryMEDLINEAnticoagulantsDiseasemedicine.diseaseRisk AssessmentPulmonary embolismFibrinolytic AgentsmedicinePulmonary angiographyBiomarker (medicine)HumansThrombolytic TherapyRisk assessmentbusinessIntensive care medicinePulmonary EmbolismDisease burdenBiomarkersCurrent opinion in pulmonary medicine
researchProduct

Systemic Thrombolytic Therapy for Acute Pulmonary Embolism: Who Is a Candidate?

2017

Pulmonary embolism (PE) is a major cause of both acute and long-term morbidity for a large number of patients worldwide, and massive PE is frequently fatal. Right ventricular (RV) dysfunction is a key determinant of prognosis in the acute phase of PE. Patients with clinically overt RV failure, that is, with cardiogenic shock or persistent hypotension at presentation (acute high-risk PE), are clearly in need of immediate reperfusion treatment with systemic thrombolysis or, alternatively, surgical or catheter-directed techniques. On the other hand, within the large group of patients presenting without hemodynamic instability, the bleeding risk of full-dose intravenous thrombolytic treatment h…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyVentricular Dysfunction Rightmedicine.medical_treatmentHemodynamicsSalvage therapy030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicineFibrinolysismedicineHumansThrombolytic TherapyDecompensation030212 general & internal medicineWatchful WaitingIntensive care medicineSalvage Therapybusiness.industryCardiogenic shockAnticoagulantsThrombolysisPrognosismedicine.diseasePulmonary embolismAcute DiseaseCardiologyPulmonary EmbolismbusinessWatchful waitingSeminars in Respiratory and Critical Care Medicine
researchProduct

Risk-adapted management of pulmonary embolism

2017

The presence and severity of right ventricular (RV) dysfunction is a key determinant of prognosis in the acute phase of pulmonary embolism (PE). Risk-adapted treatment strategies continue to evolve, tailoring initial management to the clinical presentation and the functional status of the RV. Beyond pharmacological and, if necessary, mechanical circulatory support, systemic thrombolysis remains the mainstay of treatment for hemodynamically unstable patients; in contrast, it is not routinely recommended for intermediate-risk PE. Catheter-directed pharmacomechanical reperfusion treatment represents a promising option for minimizing bleeding risk; for reduced-dose intravenous thrombolysis, the…

Riskmedicine.medical_specialtyVentricular Dysfunction Rightmedicine.medical_treatmentHemorrhage030204 cardiovascular system & hematologyDabigatran03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEdoxabanInternal medicinemedicineHumansThrombolytic Therapy030212 general & internal medicineIntensive care medicineRivaroxabanbusiness.industryAnticoagulantsDisease ManagementHematologyThrombolysisPrognosismedicine.diseasePulmonary embolismchemistryCirculatory systemCardiologyApixabanPulmonary EmbolismbusinessMajor bleedingmedicine.drugThrombosis Research
researchProduct

Comparative analysis of fibrinolytic properties of Alteplase, Tenecteplase and Urokinase in an in vitro clot model of intracerebral haemorrhage.

2020

Abstract Objective Hematoma lysis with recombinant tissue plasminogen activator (rtPA) has emerged as an alternative therapy for spontaneous intracerebral and intraventricular haemorrhage (ICH and IVH). However, the MISTIE III and CLEAR III trial failed to show significant improvement of favourable outcomes. Besides experimental and clinical trials revealed neurotoxic effects of rtPA. The demand for optimization of fibrinolytic therapy persists. Herein, we used our recently devised clot model of ICH to systematically analyse fibrinolytic properties of rtPA, tenecteplase and urokinase. Methods In vitro clots of human blood (size: 25 ml and 50 ml; age: 1.5 tenecteplase, 24 tenecteplase and 48…

Time FactorsTenecteplase03 medical and health sciences0302 clinical medicineHematomaFibrinolytic AgentsmedicineHumansThrombolytic TherapyCerebral HemorrhageUrokinaseHuman bloodDose-Response Relationship Drugbusiness.industryOptimal treatmentFibrinolysisRehabilitationmedicine.diseaseUrokinase-Type Plasminogen ActivatorIn vitroCatheterAnesthesiaTissue Plasminogen ActivatorTenecteplaseSurgeryNeurology (clinical)Fibrinolytic therapyCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgerymedicine.drugJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
researchProduct

Reduced Admissions for Cerebrovascular Events during COVID-19 Outbreak in Italy

2020

Supplemental Digital Content is available in the text.

disease outbreakMalemedicine.medical_treatment030204 cardiovascular system & hematologyItaly; cerebral hemorrhage; disease outbreaks; incidence; ischemic attack transient0302 clinical medicineEpidemiology80 and overMedicineischemic attack transientThrombolytic Therapy10178Acute ischemic stroke10177ThrombectomyAged 80 and overIschemic AttackTransientIncidence (epidemiology)Endovascular ProceduresMiddle AgedHospitalization1006210183ItalyComputingMethodologies_DOCUMENTANDTEXTPROCESSINGSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinecerebral hemorrhage; disease outbreaks; incidence; ischemic attack transient; Italy; Aged; Aged 80 and over; COVID-19; Cerebral Hemorrhage; Endovascular Procedures; Female; Hospitalization; Humans; Ischemic Attack Transient; Ischemic Stroke; Italy; Male; Middle Aged; Thrombectomy; Thrombolytic Therapymedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RevascularizationSettore MED/261015203 medical and health sciencesHumansAgedIschemic StrokeAdvanced and Specialized Nursingcerebral hemorrhagebusiness.industryOutbreakCOVID-19Emergency medicinedisease outbreaksincidenceBrief ReportsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Influencia de la alfabetización en salud sobre la anticoagulación oral: un factor aún desconocido

2018

lcsh:R5-920Health Knowledge Attitudes Practicebusiness.industryMEDLINEAnticoagulantsHealth literacyHealth knowledgeGeneral MedicineHealth Literacy03 medical and health sciences0302 clinical medicineCartas al EditorHumansMedicineThrombolytic Therapy030212 general & internal medicinelcsh:Medicine (General)Family PracticebusinessHumanities030217 neurology & neurosurgeryAtención Primaria
researchProduct

Effect of uric acid in animal models of ischemic stroke: A systematic review and meta-analysis

2020

Addition of uric acid (UA) to thrombolytic therapy, although safe, showed limited efficacy in improving patients’ stroke outcome, despite alleged neuroprotective effects of UA in preclinical research. This systematic review assessed the effects of UA on brain structural and functional outcomes in animal models of ischemic stroke. We searched Medline, Embase and Web of Science to identify 16 and 14 eligible rodent studies for qualitative and quantitative synthesis, respectively. Range of evidence met 10 of a possible 13 STAIR criteria. Median (Q1, Q3) quality score was 7.5 (6, 10) on the CAMARADES 15-item checklist. For each outcome, we used standardised mean difference (SMD) as effect size…

medicine.medical_specialtyBrain damageNeuroprotectionMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAnimal modelFibrinolytic AgentsInternal medicineStroke outcomeIschaemic strokeAnimalsHumansMedicineThrombolytic TherapyReview ArticlesIschemic Stroke030304 developmental biology0303 health sciencesbusiness.industryRecovery of FunctionRatsUric AcidNeurologychemistryMeta-analysisIschemic strokeCardiologyUric acidNeurology (clinical)Nervous System Diseasesmedicine.symptomCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryJournal of Cerebral Blood Flow & Metabolism
researchProduct

In-hospital outcomes of catheter-directed thrombolysis in patients with pulmonary embolism.

2020

AbstractAimsCatheter-directed treatment of acute pulmonary embolism (PE) is technically advancing. Recent guidelines acknowledge this treatment option for patients with overt or imminent haemodynamic decompensation, particularly when systemic thrombolysis is contraindicated. We investigated patients with PE who underwent catheter-directed thrombolysis (CDT) in the German nationwide inpatient cohort.Methods and resultsData from hospitalizations with PE (International Classification of Disease code I26) between 2005 and 2016 were collected by the Federal Office of Statistics in Germany. Patients with PE who underwent CDT (OPS 8-838.60 or OPS code 8-83b.j) were compared with patients receiving…

medicine.medical_specialtyCathetersTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineLower risk03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicineMedicineHumansDecompensationThrombolytic Therapy030212 general & internal medicineProspective StudiesRetrospective Studiesbusiness.industryMortality rateGeneral MedicineOdds ratioThrombolysismedicine.diseaseHospitalsPulmonary embolismTreatment OutcomeCohortCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismFibrinolytic agentEuropean heart journal. Acute cardiovascular care
researchProduct